drugset / Trial / NCT01153542

Study of VX-770 on Desipramine

NCT01153542

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to evaluate the effects of VX-770 on Desipramine

Timeline

Start
2010-06
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Desipramine Small molecule 50 mg Oral
Subject Ivacaftor Other / unclassified 150 mg Oral

Indications